Clinical trials: Anger
Healthy Volunteer
A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234
The objective of this two part study was to demonstrate safety, tolerability, and pharmacokinetics of RT234 in healthy volunteers.
- Trial name
- NCT05567367
- Testing
- Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI), Vardenafil Oral Tablet
- Where
- Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Respira Therapeutics, Inc.
Healthy Adults, Elderly Subjects
Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects
Multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1439 in healthy adult and elderly subjects
- Trial name
- NCT02954263
- Testing
- TD-1439
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Tuberculosis, Tuberculosis, Pulmonary
A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371
The primary objective of the study is to evaluate the safety and tolerability of single and multiple doses of TBA-7371 in healthy subjects
- Trial name
- NCT03199339
- Testing
- TBA-7371
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Global Alliance for TB Drug Development
Healthy Volunteers
FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects
The purpose of this study is to evaluate the safety and tolerability of single and multiple intravenous ascending doses of ANT3310, a novel, specific, competitive inhibitor of serine β-lactamases, alone and in combination with…
- Trial name
- NCT05905913
- Testing
- ANT3310, Meropenem
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Antabio
Skin Disease, Immune System Disease
A Study of HL40626S Tablets in Healthy Adults
This is a single-centre, randomized, double-blind, placebo-controlled Phase 1 study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of HL40626S tablets following single and…
- Conditions
- Skin Disease, Immune System Disease, Skin Diseases, Papulosquamous, Psoriasis (PsO)
- Trial name
- NCT07736586
- Testing
- HL40626S tablets
- Where
- 2 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- HighsLab Therapeutics Inc.
Diabete Mellitus
A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699
This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) of YG1699 following single and multiple ascending oral dose administration.
- Trial name
- NCT03953092
- Testing
- YG1699
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Youngene Therapeutics Inc., Ltd.
ADHD - Attention Deficit Disorder With Hyperactivity, Tendon Injuries
Hand Tendon Injuries: An Investigation Of Attention Deficit Disorder
Tendon injuries cause significant disability, loss of work capacity, and economic burden. The injury itself and its consequences impact individuals not only in terms of their ability to work but also socially and psychologically.
- Trial name
- Tendon-ADHD (NCT07126899)
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Atılım University
Depression and Anxiety Symptom, Anger
Implementing BEAM: A Scalable Digital Mental Health Program, for Families of Children Referred to Neurodevelopmental Services
Families of children with neurodevelopmental differences (NDDs) experience disproportionately high levels of parenting stress and mental health difficulties, including elevated depression, anxiety, and caregiver burden.
- Conditions
- Depression and Anxiety Symptom, Anger, Parenting, Stress (Psychology)
- Trial name
- NCT07837791
- Testing
- The Building Emotional Awareness and Mental Health (BEAM) Program
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Healthy Volunteers, Sickle Cell Disease
A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients
FT-4202 is an oral small-molecule agonist of pyruvate kinase red blood cell isozyme (PKR) being developed for the treatment of hemolytic anemias.
- Trial name
- NCT03815695
- Where
- 18 sites in United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Forma Therapeutics, Inc.
Healthy Volunteers
VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers
This is a 2-part, first-in-human dose-ranging study to evaluate the safety and pharmacokinetics of escalating doses of VNRX-7145.
- Trial name
- NCT04243863
- Testing
- VNRX-7145
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia
Natural Killer Index From Hematopoietic Stem Cell Graft
Numerous studies about the potential role of NK alloreactive during a n hematopoietic stem cells graft are based on genotypical analyses of the KIR receptors and on genotypic incompatibilities between KIR and HLA for couple…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia, Chronic Myeloid Leukemia
- Trial name
- NCT00435864
- Testing
- Blood test
- Where
- France
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital
Program Modality
Evaluation Exploring How Course Modality Influences the Effectiveness of the R3 Academy for Couples
The REFRAME project is designed to offer the R3 Academy for Couples, a robust 24-hour program, to married adults ages 18 and over in the state of California.
- Trial name
- NCT05580627
- Testing
- Livestream Modality (treatment), Live Modality (control)
- Where
- United States
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Healthy Relationships California
Healthy Subjects
MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous Zidebactam in Healthy Adults
Study to evaluate the safety and tolerability of multiple escalating doses of intravenous (IV) Zidebactam in healthy adult human subjects.
- Trial name
- NCT02674347
- Testing
- 3 g or 6 g Zidebactam
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Wockhardt
Safety Issues, Tolerability
Single Ascending Dose and Multiple Ascending Dose Study of AVR-48
This is a Phase 1 (healthy adult volunteers), 2-part, double-blind, randomized, placebo controlled trial to evaluate the safety and pharmacokinetic (PK) profiles of escalating single doses of AVR-48 versus placebo (SAD) and…
- Conditions
- Safety Issues, Tolerability, Pharmacokinetics, Pharmacodynamics
- Trial name
- NCT06847698
- Testing
- AVR-48
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AyuVis Research, Inc.
Colonic Diseases
A Clinical Phase I Study on GIC-1001 in Healthy Volunteers
The objectives of this single center, randomized, double-blinded, placebo-controlled Phase I clinical study are to evaluate the safety and tolerability of five (5) single and four (4) multiple increasing oral doses of GIC-1001…
- Trial name
- NCT01738425
- Testing
- GIC-1001; 125 mg oral tablets
- Where
- Canada
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- gicare Pharma Inc.
Ulcerative Colitis
SAD/MAD Study in Healthy Subjects and Adults With UC to Evaluate Safety, Tolerability, PK, PD of AMT-101
A randomized, double-blind placebo-controlled first in human study in approximately 36 male healthy subjects and approximately 20 male and female patients with active UC who have had an inadequate response to or demonstrated…
- Trial name
- AURIGA1 (NCT04224857)
- Testing
- AMT-101
- Where
- 4 sites in Georgia, Germany and 2 more
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Applied Molecular Transport
Cocaine Use Disorder, Substance Use Disorders
Multiple Ascending Dose Study of TMP-301 in Healthy Subjects
A PHASE 1, RANDOMIZED, PLACEBO CONTROLLED, MULTIPLE ASCENDING DOSE (MAD) STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TMP-301 IN HEALTHY SUBJECTS.
- Conditions
- Cocaine Use Disorder, Substance Use Disorders, Healthy Volunteers
- Trial name
- NCT06025396
- Testing
- Cohort 1 - TMP-301, Cohort 2 - TMP-301, Cohort 3 - TMP-301
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tempero Bio, Inc.
Inflammatory Disorder of the Respiratory Tract, Chronic Obstructive Pulmonary Disorder
SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects
The purpose of the study is to assess the safety of single doses and multiple doses of a new formulation of RPL554 in healthy subjects and subjects with chronic obstructive pulmonary disorder.
- Trial name
- NCT02307162
- Testing
- RPL554
- Where
- United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Healthy
A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy Subjects
This is a FIH, randomized, double- blind, placebo-controlled, dose -escalation study to investigate the safety, tolerability, PK, and PD of ENN0403 after single and multiple oral dose administration in healthy adult subjects.
- Trial name
- NCT05506540
- Testing
- ENN0403 1mg, ENN0403 4mg, ENN0403 10mg
- Where
- Australia
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- EnnovaBio
Healthy Volunteers, Rheumatoid Arthritis
A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis
This double-blind, randomized, placebo-controlled study will assess the safety and pharmacokinetics of ZB002 in healthy participants and in participants with rheumatoid arthritis (RA). The study consists of 2 parts.
- Trial name
- NCT05638854
- Testing
- ZB002
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Zenas BioPharma (USA), LLC